BridgeBio Oncology Therapeutics, Inc. (BBOT)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
9.35 USD
+0.13
(1.410%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 9.54 +0.19 (2.032%) ⇧ (April 17, 2026, 5:34 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:24 p.m. EDT
BBOT is currently in a volatile and uncertain phase, with a recent price drop to $8.40, near its 52-week low of $8.08. The stock's negative forward and trailing EPS, along with a negative P/E ratio, indicate poor earnings performance and lack of profitability. The recent price history shows a mix of upward and downward movements, suggesting possible short-term momentum opportunities, but the overall trend is bearish. With no dividend history, it's not suitable for income-focused investors. The forecasting model suggests a minimal positive direction, but the high H-Stat and low Ljung-Box p-value indicate potential volatility and unreliable predictions. Long-term investors should be cautious due to the lack of solid fundamentals and the company's current financial position. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.231211 |
| MSTL | 0.295847 |
| AutoETS | 0.298180 |
| AutoTheta | 0.300987 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 6.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.191 |
| Excess Kurtosis | -0.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.673 |
| Market Cap | 748,306,944 |
| Forward P/E | -4.57 |
| Beta | 0.51 |
| Website | https://bbotx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.13184774 |
| Address1 | 256 East Grand Avenue |
| Address2 | Suite 104 |
| All Time High | 14.87 |
| All Time Low | 8.08 |
| Ask | 9.4 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 484,670 |
| Average Daily Volume3 Month | 272,646 |
| Average Volume | 272,646 |
| Average Volume10Days | 484,670 |
| Beta | 0.507 |
| Bid | 9.29 |
| Bid Size | 2 |
| Book Value | 5.139 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.35 |
| Current Ratio | 12.34 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 9.6482 |
| Day Low | 9.235 |
| Debt To Equity | 0.673 |
| Display Name | BridgeBio Oncology Therapeutics |
| Earnings Call Timestamp End | 1,773,421,200 |
| Earnings Call Timestamp Start | 1,773,421,200 |
| Earnings Timestamp | 1,772,744,400 |
| Earnings Timestamp End | 1,778,097,600 |
| Earnings Timestamp Start | 1,778,097,600 |
| Ebitda | -145,539,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.237 |
| Enterprise Value | 325,612,896 |
| Eps Current Year | -2.06667 |
| Eps Forward | -2.048 |
| Eps Trailing Twelve Months | -4.3 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.6712 |
| Fifty Day Average Change | -0.32119942 |
| Fifty Day Average Change Percent | -0.03321195 |
| Fifty Two Week Change Percent | -13.184774 |
| Fifty Two Week High | 14.87 |
| Fifty Two Week High Change | -5.5199995 |
| Fifty Two Week High Change Percent | -0.3712172 |
| Fifty Two Week Low | 8.08 |
| Fifty Two Week Low Change | 1.2700005 |
| Fifty Two Week Low Change Percent | 0.15717828 |
| Fifty Two Week Range | 8.08 - 14.87 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,707,489,000,000 |
| Float Shares | 31,158,379 |
| Forward Eps | -2.048 |
| Forward P E | -4.5654297 |
| Free Cashflow | -74,194,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 92 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.27225 |
| Held Percent Institutions | 0.70341 |
| Implied Shares Outstanding | 80,032,823 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California. |
| Long Name | BridgeBio Oncology Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 748,306,944 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_623256762 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -134,044,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 747,506,566 |
| Number Of Analyst Opinions | 8 |
| Open | 9.36 |
| Operating Cashflow | -113,894,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 405 4770 |
| Post Market Change | 0.18999958 |
| Post Market Change Percent | 2.032081 |
| Post Market Price | 9.54 |
| Post Market Time | 1,776,461,678 |
| Previous Close | 9.22 |
| Price Eps Current Year | -4.5241866 |
| Price Hint | 2 |
| Price To Book | 1.8194202 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.153 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.13 |
| Regular Market Change Percent | 1.40998 |
| Regular Market Day High | 9.6482 |
| Regular Market Day Low | 9.235 |
| Regular Market Day Range | 9.235 - 9.6482 |
| Regular Market Open | 9.36 |
| Regular Market Previous Close | 9.22 |
| Regular Market Price | 9.35 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 586,325 |
| Return On Assets | -0.2975 |
| Return On Equity | -0.48233002 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 80,032,823 |
| Shares Percent Shares Out | 0.0299 |
| Shares Short | 2,256,471 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,328,433 |
| Short Name | BridgeBio Oncology Therapeutics |
| Short Ratio | 15.11 |
| Source Interval | 15 |
| State | CA |
| Symbol | BBOT |
| Target High Price | 41.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 25.375 |
| Target Median Price | 23.5 |
| Total Cash | 425,460,000 |
| Total Cash Per Share | 5.316 |
| Total Debt | 2,766,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.968885 |
| Two Hundred Day Average Change | -1.618885 |
| Two Hundred Day Average Change Percent | -0.14758883 |
| Type Disp | Equity |
| Volume | 586,325 |
| Website | https://bbotx.com |
| Zip | 94,080 |